

Anthera Pharmaceuticals Announces Presentation of Blisibimod Data at the American College of Rheumatology Annual Meeting

November 5, 2017

Presentation will highlight additional analyses of the CHABLIS-SC1, Phase 3 clinical study of blisibimod

HAYWARD, Calif., Nov. 05, 2017 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) will present additional findings from the CHABLIS-SC1, Phase 3 clinical study of blisibimod, a novel treatment that targets B-cell activating factor (BAFF), at the American College of Rheumatology (ACR) Annual Meeting in San Diego from November 3-8.

"This presentation of the CHABLIS-SC1 Phase 3 clinical study shows the salutary effects of blisibimod treatment on the successful reduction of background corticosteroid use, decreased urinary protein:creatinine ratio (UPCR), and positive impact on complement, autoantibodies, and B cell counts when administered on top of background standard-of-care medications to patients with systemic lupus erythematosus (SLE)," said Kenneth Kalunian, MD, Professor of Medicine, Division of Rheumatology, Allergy and Immunology, University of California, San Diego.

Details of Anthera Pharmaceuticals' ACR 2017 presentation are as follows:

Title: Phase 3 Trial Results with Blisibimod, a Selective Inhibitor of B-Cell Activating Factor, in Subjects with Moderate-to-Severe Systemic Lupus Erythematosus

Session: Systemic Lupus Erythematosus – Clinical Aspects and Treatment I: Novel and Current Therapies

When: Sunday, November 5, 2017; 2:30 PM - 4:00 PM

Location: San Diego Convention Center, Poster Hall C

Presentation Number: 63923

Presenter: Joan T. Merrill M.D., Oklahoma Medical Research Foundation Professor of Medicine, University of Oklahoma Health Sciences Center

All ACR abstracts are available on the conference website <https://www.rheumatology.org/Annual-Meeting>

About Anthera Pharmaceuticals

Anthera Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing products to treat serious and life-threatening diseases, including exocrine pancreatic insufficiency and IgA nephropathy. Additional information on the Company can be found at www.anthera.com.

Safe Harbor Statement

Any statements contained in this press release that refer to future events or other non-historical matters, including statements that are preceded by, followed by, or that include such words as "estimate," "intend," "anticipate," "believe," "plan," "goal," "expect," "project," or similar statements, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based on Anthera's expectations as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially, including but not limited to those set forth in Anthera's public filings with the SEC, including Anthera's Quarterly Report on Form 10-Q for the quarter ended June 30, 2017. Anthera disclaims any intent or obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as required by applicable law.

CONTACT:

Investor Relations of Anthera Pharmaceuticals, Inc.
ir@anthera.com

For Media Inquiries:
Frannie Marmorstein, 305-567-0821
frannie.marmorstein@rbbcommunications.com

www.twitter.com/antherapharma
<https://www.facebook.com/antherapharma/>
<https://www.linkedin.com/company/anthera-pharmaceuticals>

Source: Anthera Pharmaceuticals, Inc.